CryoCor files patent complaint against CryoCath
CryoCor, a medical device company focused on the treatment of cardiac arrhythmias, has filed a formal complaint with the U.S. International Trade Commission (ITC) alleging that CryoCath Technologies has engaged in unfair trade practices by infringing on several CryoCor patents with its cryoablation system.
CryoCor said it is requesting that the ITC initiate an investigation and issue an exclusion order to bar the importation into the U.S. of infringing CryoCath cryoablation products.
The complaint covers three patents exclusively licensed to CryoCor in certain fields of use related to its Cardiac Cryoablation System, including patents covering pre-cooling technologies that CryoCor considers important to CryoCath's cryoablation system, according to the San Diego-based CryoCor.
The company said this action is independent of a patent interference that has been declared by the U.S. Patent and Trademark Office between CryoCor and CryoCath, where CryoCor has been declared the senior party.
If the ITC accepts the complaint, the commission will institute a formal Section 337 investigation within 30 days.
“Importantly, an ITC investigation has a fast timeline for completion, usually just over one year. If we prevail, the ITC may issue a ban on importation of CryoCath's cryoablation system into the United States,” said Ed Brennan, PhD, president and CEO of CryoCor.
CryoCor said it is requesting that the ITC initiate an investigation and issue an exclusion order to bar the importation into the U.S. of infringing CryoCath cryoablation products.
The complaint covers three patents exclusively licensed to CryoCor in certain fields of use related to its Cardiac Cryoablation System, including patents covering pre-cooling technologies that CryoCor considers important to CryoCath's cryoablation system, according to the San Diego-based CryoCor.
The company said this action is independent of a patent interference that has been declared by the U.S. Patent and Trademark Office between CryoCor and CryoCath, where CryoCor has been declared the senior party.
If the ITC accepts the complaint, the commission will institute a formal Section 337 investigation within 30 days.
“Importantly, an ITC investigation has a fast timeline for completion, usually just over one year. If we prevail, the ITC may issue a ban on importation of CryoCath's cryoablation system into the United States,” said Ed Brennan, PhD, president and CEO of CryoCor.